Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a probiotic keep ulcerative colitis in check?

NCT ID NCT07751081

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial is testing whether a probiotic supplement called Colipral, which contains a specific strain of E. coli bacteria, can improve gut health in people with ulcerative colitis who are in remission but still have digestive issues. Participants will take either the supplement or a placebo for 60 days, then switch, so everyone gets both. The study will look at changes in gut bacteria, markers of inflammation, and symptoms to see if the probiotic helps maintain remission and ease discomfort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a food supplement containing the probiotic strain Escherichia coli 5C LMG S-33222 (Colipral)
What this could lead to
If effective, this probiotic could help maintain remission and ease gut symptoms in people with ulcerative colitis, potentially improving quality of life.
What could go wrong
This is a small, early-stage trial, and the supplement may not significantly alter gut bacteria or symptoms. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Diagnosis of UC confirmed by clinical, endoscopic and histopathological evidence. * Disease in remission phase confirmed by clinical, endoscopic and histopathological evidence for at least 6 months * Diagnosis of disorders of gut-brain interaction (DGBI): IBS-D, IBS-M, bloating, and abdominal pain * Male/female * Age in the range 18-70 years * Subjects capable of conforming to the study protocol * Subjects who have given their free and informed consent Exclusion criteria: * History of gastrointestinal disorders or gastrointestinal surgery interfering with gastrointestinal function * Subjects with untreated food intolerance, i.e. remaining symptomatic despite the withdrawal of the suspected food * Currently following a restrictive diet (for example low FODMAPs diet or vegan diet) * Females of childbearing potential, in the absence of effective contraceptive methods * Subjects who become unable to conform to protocol * Recent history or suspicion of alcohol abuse or drug addiction * Indication for the initiation of a new drug therapy during the study * History of current or recent antibiotic or probiotics use within the last 30 days * Subjects who are treated with antibiotics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Functional disorder of gastrointestinal tract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Ospedale - Univeristà Padova

    Padova, Padova, 35128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.